Search results
Showing 136 to 150 of 449 results for cardiovascular disease
pump blood around your body. This means that you may be at risk of cardiovascular disease, for example a stroke or a heart attack. You...
This guideline covers diagnosing and managing atrial fibrillation in adults. It includes guidance on providing the best care and treatment for people with atrial fibrillation, including assessing and managing risks of stroke and bleeding.
This guideline covers encouraging people to increase the amount they walk or cycle for travel or recreation purposes.
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.
This quality standard covers promoting health and preventing premature mortality among black, Asian and other minority ethnic groups. It is relevant to all age groups and all settings.
View quality statements for QS167Show all sections
Sections for QS167
- Quality statements
- Quality statement 1: Designing health and wellbeing programmes
- Quality statement 2: Peer and lay roles
- Quality statement 3: Referring people at high risk of type 2 diabetes
- Quality statement 4: Cardiac rehabilitation
- Quality statement 5: Support for people with mental health problems
- Quality statement 6: Physical health checks for people with serious mental illness
- Update information
Digital platforms to support cardiac rehabilitation: early value assessment (HTG761)
Early value assessment (EVA) on digital platforms to support cardiac rehabilitation.
This quality standard covers assessing, diagnosing and managing rheumatoid arthritis in over 16s. It describes high-quality care in priority areas for improvement.
Early value assessment (EVA) guidance on CaRi-Heart for predicting cardiac risk in suspected coronary artery disease.
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
This indicator covers establishing and maintaining a register of patients with peripheral arterial disease. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM32
Dronedarone for the treatment of non-permanent atrial fibrillation (TA197)
Evidence-based recommendations on dronedarone (Multaq) for treating non-permanent atrial fibrillation in adults.
of chronic health conditions (for example, obesity, diabetes and cardiovascular disease) for people growing older with learning...